Leuprolide · source year
4 selected, source-linked Leuprolide records carrying a 2020 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
2 represented types.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02064582 at 2026-07-30T20:21:17.072Z. Its registry update date was 2020-10-12, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02059213 at 2026-07-30T20:22:36.939Z. Its registry update date was 2020-09-16, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 213150 with status AP dated 2020-05-01, and names leuprolide acetate among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT00002633 at 2026-07-30T20:29:13.591Z. Its registry update date was 2020-04-03, and PeptideScanner's reviewed identity mapping was leuprolide.
Source: ClinicalTrials.gov ↗